| Autor: |
Ze-Shi Li, Kuo Wang, Tuo Pan, Yan-Hua Sun, Chang Liu, Yong-Qing Cheng, He Zhang, Hai-Tao Zhang, Dong-Jin Wang, Zu-Jun Chen |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
BMC Anesthesiology, Vol 22, Iss 1, Pp 1-10 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1471-2253 |
| DOI: |
10.1186/s12871-022-01663-z |
| Popis: |
Abstract Study objective The purpose of the present study was to evaluate the efficacy of levosimendan in patients with acute myocardial infarction related ventricular septal rupture (AMI-VSR) underwent cardiac surgery. Design Prospective observational cohort study with propensity score analysis. Patients There were 261 patients with AMI-VSR in our study. After 1:1 propensity matching, 106 patients (53 levosimendan and 53 control) were selected in the matched cohort. Interventions None. Measurements Patients who received levosimendan were assigned to the levosimendan group (n = 164). The patients who were not received were levosimendan assigned to the control group (n = 97). The levosimendan was initiated immediately after cardiopulmonary bypass. Then, it has been maintained during the postoperative 3 days. The poor outcomes were identified as follows: death and postoperative complications (postoperative stroke, low cardiac output syndromeneeded mechanical circulatory support after surgery, acute kidney injury (≥ stage III), postoperative infection or septic shock, new developed atrial fibrillation or ventricular arrhythmias). Main results Before matching, the control group had more length of ICU stay (6.69 ± 3.90 d vs. 5.20 ± 2.24 d, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
